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Currently, about half (51 percent) of the pregnancies in the United States are unintended and the 
United States has the highest rate of unintended pregnancies among developed nations (Guttmacher 
Institute, 2013). According to the American College of Obstetricians and Gynecologists (ACOG, 
2010), pregnancy is defi ned as implantation of a fertilized egg. A pregnancy that is unplanned, mis-
timed and/or unwanted is referred to as an unintended pregnancy (Guttmacher Institute, 2013). 
Unintended pregnancies may lead to poor maternal and child health outcomes, such as delayed pre-
natal care, premature birth, reduced likelihood of breastfeeding, maternal depression, increased risk 
of physical violence in pregnancy and physical and mental impacts on the baby (Guttmacher Insti-
tute, 2013; U.S. Department of Health and Human Services [DHHS], 2011). Both ACOG (2010) and 
Healthy People 2020 (DHHS, 2011) recognize the inherent need to reduce unintended pregnancy by 
increasing the availability of emergency contraception.
Abstract: Numerous policy changes have expanded access to emergency contraception, such as Plan B®, in recent years. Plan B® is a progesterone-based 
medication that prevents pregnancy from occurring up to 120 hours aft er unprotected intercourse by preventing ovulation and tubal transport. Increased 
access to Plan B® allows women to make independent decisions regarding reproductive health. Nurses play an important role in providing education as well 
as comprehensive, compassionate and holistic care. DOI: 10.1111/1751-486X.12186
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 Over the past decade, there have been nu-
merous advances to improve the control women 
have over their reproductive health and thus re-
duce unintended pregnancies. Th ese advances 
have been visible in the media with a plethora 
of news coverage on reproductive health options 
such as emergency contraception. Within the 
last 7 years there have been four major policy 
changes that have specifi cally increased access to 
one type of emergency contraception—Plan B®.
Diff erent political and philosophical views on 
reproductive health, including misunderstand-
ings about the safety and mechanism of action 
of Plan B®, have fueled political turmoil, heated 
debates and delayed the over-the-counter (OTC) 
availability of Plan B®. It’s imperative that nurses 
understand the science and policy surrounding 
Plan B®, as well as the needs of women accessing 
it. Th is paper reviews the history of Plan B®, in-
cluding the major policy changes, properties and 
implications for health care providers such as 
nurses, midwives and advanced practice nurses.
History of Plan B®
Emergency contraception, sometimes referred 
to as a postcoital method, is a contraceptive 
method used aft er unprotected intercourse to 
prevent pregnancy, using the ACOG defi nition 
of pregnancy. Logically, emergency contraception would be 
used aft er any of three diff erent scenarios: (1) contraceptive 
mishap or failure (i.e., missed pill, mistimed contraceptive in-
jection, broken condom); (2) spontaneous intercourse without 
contraception and (3) sexual assault with a fear of pregnancy 
(Munro, Martyn, Campbell, Graham-Bermann, & Seng, 2015). 
Before easily accessible and branded emergency contracep-
tion became available, patients and health care providers uti-
lized a variety of methods and preexisting modes of combined 
oral contraception for “emergency” situations. Originally, com-
bined oral contraceptive pills were utilized to provide preg-
nancy prevention aft er unprotected intercourse via the Yuzpe 
method, fi rst described by a Canadian pharmacist in 1974 
(Yuzpe, Th urlow, Ramzy, & Leyshon, 1974). Combined oral 
contraceptive pills are still utilized to provide pregnancy pre-
vention aft er unprotected intercourse; a list of oral contracep-
tives approved for emergency contraceptive use in the United 
States is available from Trussell, Raymond, and Cleland (2014). 
One of the dedicated options for emergency contraception 
included the progesterone-only method, Plan B® (sometimes 
incorrectly referred to as the “morning-aft er pill”), which was 
initially approved for use as a prescription product in 1999 
(Johnson & Burrows, 2007). Aft er many years of proven safety 
and effi  cacy as a prescription product, intense policy debate fol-
lowed regarding increasing its availability as an OTC product 
to adolescents and young adults. In 2009, a one-dose version of 
Plan B® became available called Plan B One-Step® (in this article 
we’ll continue to use the term Plan B® unless specifi cally refer-
ring to characteristics or policy changes of Plan B One-Step®). 
Despite the relative safety of Plan B® as an OTC medication, 
its pathway to OTC status has been met with unprecedented 
delays by both the U.S. Food and Drug Administration (FDA) 
and DHHS (see Box 1). Th ese delays have been fueled by public 
misunderstandings about how Plan B® works and unease about 
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It’s imperative that nurses 
understand the science and policy 
surrounding Plan B®, as well as 
the needs of women accessing it
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BOX 1
A History of the Status of Plan B®
Date Regulatory Change Reference
July 28, 1999 Plan B® approved for prescription use with 88 percent  Johnson and Burrows
 effi cacy within 72 hours of unprotected intercourse and  (2007)
 95 percent effi cacy within 24 hours of unprotected 
 intercourse  
April 2003 Women’s Capital Corporation applies for OTC status  Johnson and Burrows
 for Plan B® (2007)
December 16,  The U.S. FDA votes 23-4 in favor of OTC status for Plan B® Johnson and Burrows 
2003  (2007)
May 2004 FDA rejects the advice of its scientifi c committee and issues  Johnson and Burrows
 a “not approvable” letter due to “inadequate sample” of  (2007)
 younger age groups  
July 2004 Barr Labs reapplies for OTC status for Plan B® for Johnson and Burrows 
 ages 17 and older  (2007)
January 21, 2005 FDA denies initial application for OTC marketing of Plan B® Johnson and Burrows 
  (2007)
August 26, 2005 Approval of OTC Plan B® would require “profound policy  Johnson and Burrows
 changes” and “novel regulatory issues”; FDA requests public  (2007)
 comments regarding OTC Plan B® 
June 2006 Public comments reviewed and FDA ready to issue approval Johnson and Burrows 
  (2007)
August 24, 2006 Plan B® approved as a nonprescription product that could  Johnson and Burrows
 be obtained behind the counter by individuals ages 18 and  (2007)
 older with proof of age 
April 22, 2009 Plan B® behind-the-counter status expanded to individuals  FDA (2009)
 ages 17 and older 
April 4, 2013  New York judge rules that all age restrictions for all forms  Tummino v. Hamburg
 of oral emergency contraception should be lifted (2013)
April 30, 2013 Plan B One-Step® OTC status expanded to individuals  FDA (2013a)
 ages 15 and older 
June 20, 2013 FDA approves that all age restrictions for accessing  FDA (2013b)
 OTC Plan B One-Step® may be removed and generics 
 (i.e., two-tablet levonorgestrel tablets) remain age 
 restricted and behind the counter 
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methods around the globe in more than 100 countries (John-
son & Burrows, 2007). In fact, 40 other countries legalized Plan 
B® as an OTC medication prior to the United States without any 
reports of adverse events (Johnson & Burrows, 2007).
Plan B’s® initial bid for easier availability began in 2003 
when Women’s Capital Corporation submitted an application 
for OTC status (Johnson & Burrows, 2007). Despite a favorable 
vote by the FDA scientifi c committee, the FDA did not approve 
this change in status (Johnson & Burrows, 2007). Aft er Wom-
en’s Capital Corporation and Plan B® were acquired by Barr 
Labs, a second application for OTC status was submitted in 
2004 for women ages 17 and older (Johnson & Burrows, 2007). 
On August 24, 2006, Plan B® was fi nally approved as a nonpre-
scription product that could be obtained behind the counter 
by individuals ages 18 and older with an identifi cation card for 
proof of age (Johnson & Burrows, 2007). Th e importance of 
this behind-the-counter status is that any individual purchas-
ing Plan B®, which is available to all genders, had to approach 
the pharmacy counter and show a photo identifi cation to verify 
age in order to obtain the product. Th us, 
this method of availability did not provide 
the ease and anonymity that many indi-
viduals purchasing Plan B® would have 
desired, adding a new barrier to access. 
Other delays relate to fi nding providers 
and pharmacists who will write or fi ll such 
prescriptions, which can prevent women 
from accessing emergency contraception 
and possibly deter them from attempt-
ing to access it from another pharmacy 
or pharmacist (Gee, Shacter, Kaufman, & 
Long, 2008). See Figure 1 for a review of 
medication availability classifi cations. 
On April 22, 2009, access to behind-
the-counter Plan B® was expanded to in-
dividuals ages 17 and older (U.S. FDA, 
2009). In 2012, Teva Pharmaceuticals fi led 
an amendment to expand Plan B® access to 
an OTC venue for individuals ages 15 and 
older with identifi cation required for proof 
of age at checkout (FDA, 2013a). Most re-
cently, in 2013, debates about expanding 
how to provide adolescents with reproductive health care and 
education. Opponents fear that improved access to Plan B® will 
contribute to risky sexual behavior among adolescents and 
young adults, despite an abundance of evidence that this is not 
the case (Raine et al., 2005). Furthermore, there are concerns 
about a minor’s ability to consent to family planning services 
independently. However, based on the Supreme Court decision 
Carey versus Population services international (1977, 431 U.S. 
678), a minor’s right to access contraception services are pro-
tected (Th e Network for Public Health Law, 2012). Federally 
funded programs such as Medicaid and Title X also ensure that 
minors ages 13 and older must have access to confi dential fam-
ily planning services (Gudeman & Madge, 2011).  
Th is imperative, along with the new federal regulations ex-
panding the availability of Plan B One-Step® to individuals of 
any age, should abolish the concern and misconceptions about 
the ability of a minor to consent to family planning services, 
such as purchasing OTC Plan B®. Furthermore, emergency 
contraception products similar to Plan B® are used as postcoital 
FIGURE 1
Medication Availability Classifi cation
Plan B® is effective as an emergency contraceptive method by interfering 
with ovulation and tubal transport of sperm and ova; it is not 
an abortifacient, as implied by the misnomer of “the morning-after pill” 
 
Prescription
Pharmacy Access
Behind-the-counter
Over-the-counter
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individuals ages 17 and older (i.e., My Way® and Next Choice 
One Dose®). For example, one-tablet generic formulations 
of emergency contraception pills such as My Way® and Next 
Choice One Dose® should also be available to consumers ages 
17 and older as an OTC product located on pharmacy shelves 
(at this time, though, they also remain in picture form or lock-
boxes necessitating that a pharmacy employee be involved in 
acquiring the product), while generic two-tablet formulations 
of levonorgestrel will remain available to consumers ages 17 
and older as a behind-the-counter product. Based on recent 
changes to the availability of Plan B One-Step®, it’s possible that 
we will continue to see changes in the way that all emergency 
contraception pills are dispensed.
Research Evidence
Plan B® has been produced as two products: (1) a 0.75 mg 
levonorgestrel (progesterone) tablet divided into two doses 
taken 12 hours apart or (2) as Plan B One-Step®, a single 1.5 
mg dose (Scolaro, 2007). Plan B One-Step® is the product cur-
rently available OTC. Plan B® can be safely taken by almost 
every woman in need of emergency contraception; according 
to the package insert, the only contraindication to Plan B® is 
a known or suspected pregnancy (Duramed Pharmaceuticals, 
2009). However, Plan B® will not harm an existing pregnancy 
nor will it increase the frequency of fetal abnormalities (Davi-
doff  & Trussell, 2006). 
Plan B® is eff ective as an emergency contraceptive method 
Plan B® to an OTC product that will be displayed in pharmacy 
aisles and about the reduction and eventual elimination of age 
restrictions were introduced. On April 4, 2013, a federal judge 
in New York mandated that all age restrictions be removed 
from purchasing Plan B One-Step® and that it be available as a 
true OTC product in pharmacy aisles (Tummino v. Hamburg, 
2013). Th is ruling was partially followed on April 30, 2013, 
when Plan B One-Step® was approved as an OTC product for 
individuals ages 15 and older with identifi cation for proof of age 
(FDA, 2013a). Further expansion of Plan B One-Step® occurred 
in June 2013 when it became available as an OTC product to all 
age groups with no identifi cation required at checkout (FDA, 
2013b). Th is OTC status means that the medication should be 
available in aisles next to pregnancy tests, condoms, acetami-
nophen and other products that are available without limita-
tions. However, at this time pharmacies are still grappling with 
how this product should be displayed. Th us, the current avail-
ability of OTC Plan B One-Step® is generally either pictures of 
the medication displayed in aisles referring potential consum-
ers to ask the pharmacist for the medication or the medication 
in a lockbox in the aisles requiring that the consumer seek the 
help of a pharmacy employee in order to purchase it. Th erefore, 
even with the legal ability to purchase Plan B One-Step®, there 
are still unnecessary barriers to access.
Th ese policy changes have important implications for other 
forms of emergency contraception that are currently regulated 
by prescription (i.e., ellaOne®) or are only available OTC to Ph
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(body mass index [BMI] > 25; Glasier et al., 2011) and even 
newer research cautions that levonorgestrel-based emergency 
contraception is less eff ective in women weighing 165 pounds 
or more and is not eff ective at all in women weighing 176 
pounds or more (Faculty of Sexual & Reproductive Healthcare, 
2013). At this time no prescribing or packaging changes to lev-
onorgestrel-based emergency contraceptive products (such as 
Plan B®, Next Choice One Dose® or My Way®) have been made 
until more data are available (Faculty of Sexual & Reproductive 
Healthcare, 2013). Nonetheless, providers should consider al-
ternative methods of emergency contraception such as a copper 
intrauterine device (IUD) like Paragard or ulipristal acetate like 
ellaOne®, a selective progesterone receptor modulator that may 
be more appropriate for women weighing 165 pounds or more.
by interfering with ovulation and tubal transport of sperm and 
ova; it is not an abortifacient, as implied by the misnomer of 
“the morning-aft er pill” (Davidoff  & Trussell, 2006; Scolaro, 
2007). Studies demonstrate that Plan B® can be eff ective for 
up to 120 hours aft er administration following unprotected 
intercourse, but data indicate a higher risk of therapeutic fail-
ure aft er 72 hours (Scolaro, 2007). Plan B® should be taken as 
soon as possible aft er unprotected intercourse to benefi t from 
higher effi  cacy rates that range from 52 percent to 94 per-
cent (Dominguez et al., 2010). Plan B® has also demonstrated 
high effi  cacy rates when taken aft er sexual assault (Choi, Kim, 
Hwang, Lee, & Kong, 2013). 
Plan B® is generally tolerated quite well, but side eff ects can 
include nausea, headache, fatigue and abdominal pain (Scola-
ro, 2007). Menses usually resume within 1 week before or aft er 
the expected time; however, some users may experience irregu-
lar bleeding and changes in their menstrual cycle (i.e., lighter 
or heavier fl ow) based on when they took the medication dur-
ing their menstrual cycle (Allen & Goldberg, 2007). Th e active 
component of Plan B®, levonorgestrel, has a robust safety histo-
ry with no link to venous thromboembolism or death (Scolaro, 
2007). In fact, Plan B® is considered very safe in comparison to 
other OTC medications such as acetaminophen, dextrometho-
rphan and caff eine, which have been linked to unintentional 
overdose and even death (Rafi e et al., 2013). 
Relatively new research indicates that Plan B® has demon-
strated decreased effi  cacy among women considered overweight 
Women might be accessing OTC 
Plan B® without the resources to 
make informed decisions about 
follow-up care for STI testing, 
future contraception and what 
to do if Plan B® isn’t effective
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Women’s Needs
Research on Plan B® has focused on safety, mechanism of ac-
tion, eff ects on promiscuity and availability; however, there has 
been limited research conducted on the needs of individuals 
using Plan B® with regard to follow-up care, education and rea-
son for use. Plan B® is now available to a diff use population and 
it’s therefore necessary to consider the needs of any individual 
who may be utilizing it as a postcoital method. 
Two years aft er Plan B® was released behind the counter 
to women ages 18 and older, the rate of women using it dou-
bled (Kavanaugh, Williams, & Schwarz, 2011), with the most 
common individual during this time being a single, college-
educated woman between the ages of 18 and 29 (ACOG, 2010; 
Kavanaugh et al., 2011). Despite this increased use, the Na-
tional Survey of Family Growth conducted from 2006 to 2008 
demonstrated that the number of women receiving counseling 
about emergency contraception from their health care pro-
viders was relatively unchanged from 2002 (Kavanaugh et al., 
2011). In fact, only 4 percent of women in the National Survey 
of Family Growth who reported a Pap test or pelvic exam with-
in the last year reported receiving counseling about emergency 
contraception from their health care providers (Kavanaugh et 
al., 2011). Additionally, the cost of Plan B® still limits the pop-
ulation that can use it, with reported ranges from $32 to $65 
(American Society for Emergency Contraception, 2013). Th is 
price does appear to be much lower in university and college 
pharmacy settings (Munro et al., 2015).
According to ACOG (2010), aft er emergency contraceptive 
use women should be informed about additional needs includ-
ing resources for sexually transmitted infection (STI) testing 
and continuing contraception. With the increased availability 
of Plan B®, it’s now possible that women can access the medi-
cation in a retail setting without any interaction with a health 
care provider (Ragland, Payakachat, & Staff ord, 2014). Fur-
thermore, women oft en seek information about reproductive 
health options from health care personnel, friends and family 
and now the Internet. A recent study of the accuracy of infor-
mation about emergency contraception on the Internet re-
vealed that most websites provide accurate information about 
acquisition and use of emergency contraception but failed to 
address follow-up care and what a woman should do in a situ-
ation in which emergency contraception isn’t eff ective (Adrian, 
Kim, Chu, & Kaneshiro, 2013). Th us, women might be access-
ing OTC Plan B® without the resources to make informed deci-
sions about follow-up care for STI testing, future contraception 
and what to do if Plan B® isn’t eff ective.
OTC Plan B® is an important emergency contraceptive op-
tion because it enables women to make their own decisions 
regarding their reproductive health, which in most instances 
is a positive change in health care. In some instances, how-
ever, women utilizing Plan B® may be in desperate need of 
additional resources and follow-up care. For example, sexual 
BOX 2
Nursing Roles Regarding 
Emergency Contraception
Health education
•  Educate women about the mechanism of ac-
tion of emergency contraception, such as Plan 
B® 
•  Educate women and the public on the avail-
ability of emergency contraception, such as 
Plan B®
Compassionate care
• Employ a nonjudgmental attitude when
• Educating others about emergency contra-
ception
• Providing care to those who have used 
emergency contraception
• Interacting with those that choose not to 
use emergency contraception
Policy advocacy
•  Remain abreast about policy changes regarding 
the provision of reproductive health resources, 
such as Plan B®, and learn how you can impact 
local, state and national health care policies
Comprehensive health care
•  Ensure that women utilizing OTC emergency 
contraceptives are aware of the potential need 
for additional care such as
• Testing for STIs
• More reliable forms of regular or long-term 
contraception
• Options if emergency contraception is not 
effective
Holistic care
•  Be aware that some women utilizing emer-
gency contraception may be doing so in the af-
termath of a sexual assault. These women are 
especially in need of holistic, patient-centered 
care in which the health care professional can 
help make them aware of and locate additional 
resources for postassault care such as medical, 
psychological, advocacy and legal care.
Sources: ACOG (2010), AWHONN (2012), Kavanaugh et al. 
(2011), Munro et al. (2015), Westley and Schwarz (2012).
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assault survivors might be foregoing postassault care services 
to obtain Plan B® and comprehensive care as they might have 
when it was available only by prescription (Munro et al., 2015). 
Th is presents the possibility of missed opportunities for addi-
tional medical, legal and psychological care that is considered 
the standard of care for postassault survivors.
Nursing Practice Implications
All health care providers, including nurses, midwives and ad-
vanced practice nurses, must be knowledgeable about emer-
gency contraceptive options and should be prepared to educate 
women regarding the mechanism of action, availability, side ef-
fects and public perception of options. Th is broad understand-
ing is necessary to provide comprehensive, unbiased education 
to women and other providers regarding emergency contracep-
tion and its use. Recent studies have indicated that despite the 
increased availability of Plan B® there are still a num-
ber of barriers to access, including ethical and moral 
dilemmas and health care providers’ misperceptions 
about the current dispensing regulations (Wilkin-
son, Vargas, Fahey, Suther, & Silverstein, 2014). 
According to the American Nurses Association 
(2014), nurses focus on health promotion and pre-
vention by protecting and optimizing the health of 
all groups including individuals, their families, pop-
ulations and communities. Th is imperative means 
that nurses must be abreast of current policies re-
garding reproductive health and be able to provide 
education to women on diff erent forms of contra-
ception (Association of Women’s Health, Obstetric 
and Neonatal Nurses [AWHONN], 2012). Nurses 
of all levels of education can provide compassion-
ate, comprehensive, holistic care in addition to pro-
viding health education to all individuals in need 
of emergency contraception (see Box 2). Nurses 
have a broad understanding of women’s reproduc-
tive health care issues and must advocate for their 
patients through local, state and/or national policy 
change beyond the individual care they provide. 
Nurses, midwives and advanced practice nurses 
can utilize their skills in health education and pre-
vention to educate women about Plan B One-Step® 
during annual visits, family planning visits and STI visits to in-
crease awareness before the medication is procured, or at the 
time it is needed in the emergency department or hospital in-
patient settings (Westley & Schwarz, 2012). Counseling about 
emergency contraception remains one of the strongest predic-
tors of its use (Kavanaugh et al., 2011). Nurses can be aware of 
resources for women, health care professionals and the general 
community (see Box 3). 
Nurses are oft en consulted by family, friends and members 
of the community for various reasons, and they can provide 
accurate, factual information. It’s essential that everyone, re-
gardless of gender, is educated on the availability of emergency 
contraception, such as Plan B One-Step®, before they need it 
(Schrager et al., 2014). Additionally, it’s helpful for nurses to 
have a basic knowledge of current emergency contraceptive 
prices, availability and side eff ects while providing health edu-
cation (see Box 4). Finally, nurses and other clinicians must be 
aware of personal biases and still be able to provide safe, com-
prehensive reproductive health care. If health care providers 
feel uncomfortable talking about Plan B® or caring for a woman 
who has used it, then they must be self-aware enough to have 
another provider care for that woman.
Conclusion
In conclusion, emergency contraception, such as Plan B®, af-
fords women more control over their health and can reduce 
Nurses have a broad understanding 
of women’s reproductive health care 
issues and must advocate for their 
patients through local, state and/
or national policy change beyond 
the individual care they provide
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BOX 3
Selected Resources 
Website
ellaOne® 
www.ella.rx.com
Emergency Contraception 
not-2-late.com (ec.princeton.edu)
Guttmacher Institute
www.guttmacher.org/statecenter/spibs/spib_EC.pdf 
International Consortium for 
Emergency Contraception 
www.cecinfo.org 
Offi ce of Women’s Health
www.womenshealth.gov/publications/
our-publications/fact-sheet/emergency-
contraception.cfm#a
Plan B® Website
www.planbonestep.com
Planned Parenthood 
www.plannedparenthood.org/health-topics/
emergency-contraception-morning-after-pill-
4363.asp 
TeensHealth
kidshealth.org/teen/sexual_health/contraception/
contraception_emergency.html
World Health Organization
www.who.int/mediacentre/factsheets/fs244/en/
 
Highlights
• Kwik med—free consultation and next-day 
shipping
• Tab for health care professionals 
• Tab with prescribing information 
• Locate emergency contraception by zip code
• Health care provider tab
• Patient education
• Evidence-based information for health care 
providers 
• Information about using emergency contraception 
in the wake of sexual assault 
• Country-by-country facts on availability and ac-
cess to emergency contraception
• More information on the opposition to emergency 
contraception and the legal issues surrounding it 
• Government website with useful information and 
fact sheet
• As of this writing, has not been updated with 
most recent policy changes 
• Store locator by zip code
• $10 off coupon
• Tab for health care professionals
• Local offi ce fi nder
• Able to provide prescriptions to patients and dis-
pense emergency contraception in offi ce based on 
a sliding-fee scale
• Comprehensive fact sheet about available options 
• Focused on educating adolescents 
• Audio and Spanish option 
• Global reproductive health information for health 
care providers 
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